Deltec Asset Management LLC trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 8.0% during the 1st quarter, Holdings Channel.com reports. The fund owned 11,500 shares of the financial services provider’s stock after selling 1,000 shares during the quarter. Deltec Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $1,578,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of IBB. International Assets Investment Management LLC purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter valued at approximately $76,425,000. Global Assets Advisory LLC bought a new stake in iShares Biotechnology ETF during the 1st quarter valued at $66,059,000. Gray Foundation purchased a new stake in iShares Biotechnology ETF during the 4th quarter valued at $17,890,000. Miller Investment Management LP grew its holdings in iShares Biotechnology ETF by 2,394.4% in the 4th quarter. Miller Investment Management LP now owns 90,122 shares of the financial services provider’s stock worth $12,243,000 after acquiring an additional 86,509 shares during the last quarter. Finally, Gateway Advisory LLC purchased a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at about $9,829,000. 62.45% of the stock is owned by hedge funds and other institutional investors.
iShares Biotechnology ETF Stock Performance
Shares of iShares Biotechnology ETF stock traded down $0.65 during trading on Friday, reaching $137.26. 1,282,683 shares of the stock were exchanged, compared to its average volume of 1,131,735. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $141.16. The stock’s fifty day moving average is $134.42 and its 200 day moving average is $134.88.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Dividend Payout Ratio Calculator
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 6/24 – 6/28
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.